Mesoblast Limited (MESO) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$14.80
Price Target
$11.50
Target Range
$11.00 — $12.00
Analyst Rating
Buy
Forward P/E—
Trailing P/E-17.6x
Forward PEG—
Implied Growth+54.8%
Median Target$11.50
Analyst Spread8.7%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$11
-25.7%
Consensus
$12
-22.3%
Bull Case
$12
-18.9%
MESO Price Target Analysis
Updated May 8, 2026As of May 8, 2026, Mesoblast Limited (MESO) has a Wall Street consensus price target of $11.50, based on estimates from 11 covering analysts. With the stock currently trading at $14.80, this represents a potential downside of -22.3%. The company has a market capitalization of $1.91B.
Analyst price targets range from a low of $11.00 to a high of $12.00, representing a 9% spread in expectations. The median target of $11.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,4 rating it Hold, and 2 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, MESO trades at a trailing P/E of -17.6x. Analysts expect EPS to grow +54.8% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+1002.0%
Avg Forward P/E179.7x
Peers with Coverage9 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 FATEFate Therapeutics, Inc. | $280M | $2.43 | $39.50 | +1525.5% | Buy | — | 31 |
 MDXGMiMedx Group, Inc. | $548M | $3.69 | $10.00 | +171.0% | Buy | 295.2x | 15 |
 ANIKAnika Therapeutics, Inc. | $203M | $15.14 | — | — | Buy | — | 6 |
 RGENRepligen Corporation | $7.1B | $126.43 | $168.00 | +32.9% | Buy | 64.3x | 23 |
 CYTKCytokinetics, Incorporated | $9.1B | $74.29 | $92.50 | +24.5% | Buy | — | 34 |
 CRSPCRISPR Therapeutics AG | $5.1B | $52.42 | $63.00 | +20.2% | Buy | — | 38 |
 NTLAIntellia Therapeutics, Inc. | $1.6B | $13.71 | $20.88 | +52.3% | Buy | — | 39 |
 BEAMBeam Therapeutics Inc. | $3.2B | $31.47 | $40.83 | +29.7% | Buy | — | 27 |
 EDITEditas Medicine, Inc. | $297M | $3.03 | $6.00 | +98.0% | Buy | — | 25 |
 SGMOSangamo Therapeutics, Inc. | $22M | $0.10 | $7.25 | +7064.0% | Hold | — | 14 |
Upside Potential Comparison
SGMOFATEMDXGEDITNTLARGENBEAMCYTKSee MESO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MESO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MESO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonMESO — Frequently Asked Questions
Quick answers to the most common questions about buying MESO stock.
What is the MESO stock price target for 2026?
MESO's consensus price target is $11.5, -22.3% below the current price of $14.8. The 11 analysts tracking MESO see downside risk at present valuations.
Is MESO a buy, sell, or hold?
MESO has a consensus rating of "Buy" based on 11 Wall Street analysts. The rating breakdown is mixed, with 4 Hold ratings making up the largest segment. The consensus 12-month price target of $11.5 implies -22.3% downside from current levels.
Is MESO stock overvalued or undervalued?
MESO's current price is $14.8 with a consensus target of $11.5 (-22.3% implied move). Analyst estimates suggest the stock is overvalued at current levels.
How high can MESO stock go?
The most bullish Wall Street analyst has a price target of $12 for MESO, while the most conservative target is $11. The consensus of $11.5 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover MESO stock?
MESO is moderately covered, with 11 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 4 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the MESO stock forecast?
The 12-month MESO stock forecast based on 11 Wall Street analysts shows a consensus price target of $11.5, with estimates ranging from $11 (bear case) to $12 (bull case). The median consensus rating is "Buy".
Should I buy MESO stock?
Analysts are cautious on MESO, with 2 Sell ratings and a price target of $11.5 (-22.3% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do MESO price targets vary so much?
MESO analyst price targets range from $11 to $12, a 9% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $11.5 consensus represents the middle ground.